<DOC>
	<DOCNO>NCT00765466</DOCNO>
	<brief_summary>This open label , Phase II , multi-center study design evaluate effect AVR118 administer patient systemic symptom relate recurrent metastatic cancer may may undergo anti-cancer treatment . During initial , induction treatment phase study , AVR118 , 4.0 mL , give subcutaneously day 28 day . Patients respond trial period dose eligible continue AVR118 physician believe would beneficial , safety concern raise .</brief_summary>
	<brief_title>A Phase II Open Label , Multi-Center Study With AVR118 Anorectic Patients With Recurrent Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Appetite Depressants</mesh_term>
	<criteria>Histologically confirm solid tumor cancer , leukemia , lymphoma , multiple myeloma . Concurrent anticancer treatment , chemotherapy radiation therapy permit except neoadjuvant adjuvant program . Between age 1885 . Symptoms recurrent metastatic cancer anorexia predominant symptom , necessarily associate cachexia , attribute anemia , concomitant illness , obstruction loss organ function . Karnofsky performance status 40 % Palliative Prognostic Score ( PaP ) less 6 Patient expect able remain study protocol two month . Pretreatment laboratory data within 7 day enrollment : Hemoglobin &gt; 8.5 g/dL , stable dos ( hematocrit stable within 1 gram dose stable one month ) erythropoietin similar medication . Absolute neutrophil count ( ANC ) 1,500/mm3 . Platelets 50,000/mm3 . Total bilirubin 2.0 ALT AST 2.5 time ULN , , patient liver metastasis , 5 time ULN . Creatinine 1.5 mg/dL . Normal TSH Testosterone level determine . Voluntary write informed consent performance studyrelated procedure part normal medical care . Ability selfadminister subcutaneous medication assistant nurse available , keep compliance journal document injection home . If antidepressant , dose must stabilize least 30 day . Female patient postmenopausal , surgically sterilize , willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male patient agree use acceptable barrier method contraception study Patient uncontrolled brain metastasis central nervous system disease . Patient mechanical , nonreversible reason able eat , potential develop malignant bowel obstruction course induction phase treatment , patient require PEG obstruction . Patient major surgery within four week enrollment . Patient uncontrolled concomitant illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . In Investigator 's opinion , potentially interfere completion treatment accord protocol . Female patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Explore effect AVR118 4.0 mL , give subcutaneously appetite</keyword>
</DOC>